Living Insights Newsletter February 2017
Filed with ASX · · 2 pages · English
Algorae Pharmaceuticals Limited on 6ix
Earlier from Algorae Pharmaceuticals
- Approval granted for group 3 in Parkinsons trial
- US choroid plexus cells patent application published
- Group 2 Parkinsons trial patients treatment completed
- Reinstatement to Official Quotation
- Suspension from Official Quotation
Later from Algorae Pharmaceuticals
- Treatment completed for all patients in Parkinsons trial
- LCT collaborates with CBR to extend product pipeline
- NTCELL continues to halt progression of Parkinsons disease
- Preliminary Final Report and Financial Statements
- Appendix 4C Quarterly Cash Flow Report 30 September 2017
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals